June 26, 2014 3:17 am
US Orphan Drug Market Outlook 2018
Academia.edu
US Orphan Drug Pipeline Insight by Phase & Indication 5.1 Research 5.2 Preclinical 5.3 Phase I 5.4 Phase I/II 5.5 Phase II 5.6 Phase II/III 5.7 Phase III …
http://www.academia.edu/7453102/US_Orphan_Drug_Market_Outlook_2018 …………… download at this site
Market Overview
In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA introduced incentives for developing such drugs. This step taken by the FDA was successful in creating a thriving market for orphan drugs. It was in the USA first that a special law exclusively for governing orphan drugs was framed in the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan drugs. The FDA also has been continuously increasing its efforts to support this market by providing significant financial and non-financial incentives to the pharmaceutical companies to attract them. This has been one of the major drivers of growth for the US orphan drugs market.
Figure 3-1: US Orphan Drug Market (US$ Billion), 2012-2018
2012201320142015201620172018
Source: KuicK Research
see my profile
http://ictmumbai.academia.edu/AnthonyMelvinCrastoPhD
Posted by DR ANTHONY MELVIN CRASTO Ph.D
Categories: 0rphan drug status
Tags: Orphan Drug, us
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.